Johnson & Johnson (NYSE:JNJ) Posts Earnings Results, Beats Expectations By $0.09 EPS

Johnson & Johnson (NYSE:JNJ - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09, Zacks reports. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the prior year, the business earned $2.82 EPS. The business's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson updated its FY 2025 guidance to 10.800-10.900 EPS.

Johnson & Johnson Trading Up 0.7%

Shares of JNJ stock traded up $1.16 on Friday, reaching $164.14. 3,649,006 shares of the stock were exchanged, compared to its average volume of 8,122,752. The stock has a market cap of $394.94 billion, a PE ratio of 17.57, a P/E/G ratio of 2.21 and a beta of 0.41. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The stock has a 50 day moving average price of $154.10 and a 200 day moving average price of $154.84.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.17%. Johnson & Johnson's payout ratio is currently 55.61%.

Institutional Investors Weigh In On Johnson & Johnson

An institutional investor recently raised its position in Johnson & Johnson stock. United Bank increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 110.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,279 shares of the company's stock after purchasing an additional 4,876 shares during the period. United Bank's holdings in Johnson & Johnson were worth $1,539,000 as of its most recent SEC filing. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent research reports. Guggenheim raised their price target on Johnson & Johnson from $164.00 to $167.00 and gave the stock a "neutral" rating in a research note on Thursday. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price objective for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Bank of America raised their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday. Raymond James Financial cut their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Finally, UBS Group reissued a "buy" rating and issued a $190.00 price objective (up from $180.00) on shares of Johnson & Johnson in a research note on Thursday. Eleven investment analysts have rated the stock with a hold rating, nine have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average target price of $174.11.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.